ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Is an Arthritis Vaccine Using Genetically Reprogrammed Stem Cells on the Horizon?

Elizabeth Hofheinz, MPH, MEd  |  August 13, 2017

The words genetically modified are making people run for the hills these days. Not so when it comes to arthritis care, however. In the lab of one pioneering researcher, genetic engineering is catapulting arthritis treatment years ahead. Farshid Guilak, PhD, is a professor in the Department of Orthopaedic Surgery at Washington University, St. Louis, and…

Filed under:ConditionsResearch Rheum Tagged with:anti-inflammatory drugArthritisgeneticinflammationResearchRheumatic Diseaserheumatologystem cellvaccine

Hundreds of Diseases. One Voice.

Carina Stanton  |  August 5, 2017

Continually building awareness and understanding of rheumatic diseases is critical to both our profession and patient care, according to Kelly Weselman, MD, a rheumatologist in Smyrna, Ga., and a passionate advocate involved in planning the ACR’s annual Rheumatic Disease Awareness Month (RDAM). “Unlike cancer patients, whose disease is well known, patients battling a rheumatic disease…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Hundreds of DiseasesOne VoiceRheumatic Disease Awareness Month (RDAM)Simple TasksTerry Bradshaw

U.S. FDA Panel Votes Against Approval of Arthritis Drug Sirukumab

Toni Clarke  |  August 2, 2017

(Reuters)—The benefits of Johnson and Johnson’s experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 12-1 that the drug should not be approved, citing safety concerns, including an imbalance in the number of deaths in patients taking sirukumab…

Filed under:Drug UpdatesRheumatoid Arthritis Tagged with:Johnson and JohnsonRheumatoid arthritissirukumabU.S. Food and Drug Administration

Republican Bid to Gut Obamacare Fails in Senate

Yasmeen Abutaleb, Amanda Becker & David Morgan  |  July 28, 2017

WASHINGTON (Reuters)—A U.S. Senate led by Donald Trump’s fellow Republicans dealt the president a harsh blow on Friday, failing to move ahead with a major campaign promise to dismantle Obamacare as they fell one vote short of passing healthcare legislation. Three senators—John McCain (R-Az.), Susan Collins (R-ME) and Lisa Murkowski (R-Ala.)—joined Senate Democrats in the…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceU.S. SenateU.S. Senate health bill

Obamacare Repeal Battle Back on Senate Floor

Richard Cowan  |  July 26, 2017

WASHINGTON (Reuters)—After a months-long struggle, Republicans have succeeded in bringing Obamacare repeal legislation, a centerpiece of their 2016 election campaigns, to a debate on the U.S. Senate floor. Now the hard part begins. Republicans, deeply divided over the proper role of the government in helping low-income people receive healthcare, eked out a procedural win on…

Filed under:Legislation & Advocacy Tagged with:Obamacare repeal legislationSenate vote

McCain to Return for Pivotal U.S. Senate vote on Healthcare

James Oliphant  |  July 25, 2017

WASHINGTON (Reuters)—Sen. John McCain (R-Az.) will return to the U.S. capitol on Tuesday to play what could be a crucial role in salvaging Republican efforts to repeal Obamacare and keep their years-long pledge to unwind the 2010 healthcare overhaul. McCain, who is battling brain cancer, is set to help decide whether the repeal push will…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceObamacareSenateU.S. Senate health bill

U.S. Senate Republicans Complain of Disarray in Healthcare Effort

Susan Cornwell and Amanda Becker  |  July 20, 2017

WASHINGTON (Reuters)—U.S. Senate Republicans, scolded by President Donald Trump for failing to overturn Obamacare, tried to salvage their seven-year effort for a new healthcare law on Thursday, but leading senators indicated frustration over shifting goal posts. Trump on Wednesday told the Senate’s fractured Republican majority to revive a bill to repeal and replace Obamacare that…

Filed under:Legislation & Advocacy Tagged with:new healthcare lawObamacare repealrepeal and replace billSenator John McCainU.S. Senate Republicans

2 Biosimilars Make Their Way Toward the European Market

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2017

Two biosimilar treatments, Rixathon and Imraldi, are moving closer to market release in Europe for the treatment of rheumatic and other diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiosimilarsEuropean Medicines AgencyPsoriasisrituximabRixathon

Hepatitis Virus, Rheumatic Disease Connection Explored

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Leonard H. Calabrese, DO, professor of medicine at Cleveland Clinic in Ohio, presented on emerging concepts of viral infections and rheumatic disease at the ACR’s State-of-the-Art Clinical Symposium in April. “We are at a pivotal point in rheumatology in understanding the relationship between viruses and rheumatic disease,” began Dr. Calabrese. “It’s a very exciting time.” Dr. Calabrese…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)comorbiditiesconnectiondirect-acting anti-viralsdrug therapyhepatitisResearchrheumatologysymptomTreatmentVasculitisvirus

Myositis AutoantibodiesTriggered by Statins

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—On a Saturday morning in Chicago, Chester V. Oddis, MD, director of the Myositis Center at the University of Pittsburgh, explained to a crowded room of about 500 rheumatologists attending the ACR’s State-of-the-Art Clinical Symposium in April how best to use myositis autoantibodies in clinical care. He began with an overview of the different types of…

Filed under:ConditionsMeeting ReportsMyositisResearch RheumSoft Tissue Pain Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)dermatomyositisDiagnosismusclemyositisPainpatient carepolymyositisResearchrheumatologistrheumatologyStatinTreatmentweakness

  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences